SG Americas Securities LLC Has $243,000 Stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

SG Americas Securities LLC grew its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 44.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,036 shares of the company’s stock after acquiring an additional 4,291 shares during the period. SG Americas Securities LLC’s holdings in Entrada Therapeutics were worth $243,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in TRDA. US Bancorp DE bought a new stake in shares of Entrada Therapeutics during the 3rd quarter valued at about $42,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Entrada Therapeutics by 34.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock valued at $226,000 after buying an additional 3,644 shares during the period. Public Employees Retirement System of Ohio boosted its holdings in shares of Entrada Therapeutics by 89.1% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 16,259 shares of the company’s stock worth $260,000 after buying an additional 7,659 shares in the last quarter. BayBridge Capital Group LLC acquired a new stake in shares of Entrada Therapeutics during the 3rd quarter worth approximately $464,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Entrada Therapeutics in the 3rd quarter valued at $542,000. 86.39% of the stock is owned by institutional investors.

Entrada Therapeutics Trading Down 3.6 %

Shares of TRDA stock opened at $13.48 on Friday. The firm has a fifty day simple moving average of $16.41 and a two-hundred day simple moving average of $16.57. Entrada Therapeutics, Inc. has a 12 month low of $11.35 and a 12 month high of $21.79. The firm has a market capitalization of $504.42 million, a PE ratio of 8.48 and a beta of -0.17.

Insider Activity

In other Entrada Therapeutics news, CFO Kory James Wentworth sold 8,637 shares of Entrada Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $19.98, for a total transaction of $172,567.26. Following the completion of the transaction, the chief financial officer now owns 73,849 shares in the company, valued at approximately $1,475,503.02. The trade was a 10.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Natarajan Sethuraman sold 2,700 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $20.04, for a total value of $54,108.00. Following the completion of the sale, the insider now directly owns 160,888 shares of the company’s stock, valued at approximately $3,224,195.52. This trade represents a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 41,681 shares of company stock worth $851,199 over the last three months. 7.59% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

TRDA has been the topic of several research analyst reports. Roth Capital raised shares of Entrada Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Roth Mkm initiated coverage on shares of Entrada Therapeutics in a research report on Thursday, December 5th. They set a “buy” rating and a $29.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research report on Tuesday. Finally, Oppenheimer upped their price target on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 6th.

Entrada Therapeutics Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.